IntelGenx Technologies Corp. and Cary Pharmaceuticals Inc. announce enrollment of Phase I Pilot Study for QuitPak®

March 26, 2007

Saint Laurent, Quebec, and Great Falls, Virginia -(CCNMatthews – Feb. 7, 2007) - IntelGenx Technologies Corporation (OTCBB:IGXT)("IntelGenx" or the "Company") and Cary Pharmaceuticals today announced that enrollment of the subjects for the first Phase I pilot study for Cary Pharmaceutical’s formulation has commenced. QuitPak® is Cary’s proprietary combination product containing Bupropion and Mecamylamine and is intended as an alternative therapy in smoking cessation. 

The purpose of the study is to determine the suitability of IntelGenx’ newly developed extended-release formulation for the once-daily administration of Bupropion and Mecamylamine. In the course of the study, rate and extent of the absorption of the two actives will be monitored. The data obtained from this trial will be used to determine if the formulation is suitable for once-daily co-administration of the two actives.

“We are very exited about testing INT003/05 for the first time in humans. The data gathered during this trial will provide important information regarding the suitability of our new extended-release formulation for further Phase I and IIb studies that will be conducted later this year. The partnership with Cary Pharmaceuticals represents an important element in the development of our company.” said Dr. Horst Zerbe, Chief Executive Officer of IntelGenx Corp.

“This is the first clinical trial involving a product resulting from our development cooperation with Intelgenx Corp. The study represents an important step in our development efforts for a sustained-release formulation for QuitPak® that will be used by the Company to conduct its Pharmacokinetics and Phase IIb clinical trials.” added Doug Cary, Chief Executive Officer of Cary Pharmaceuticals.

IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films.  The company’s research and development pipeline includes products for the treatment of osteoarthritis, pain management, hypertension, and smoking cessation.

Cary Pharmaceuticals is a pharmaceutical development company. The Company is advancing the development of its two lead products, Tempol, for the treatment of essential hypertension and QuitPak®, for smoking cessation, through Phase IIb clinical trials.